Seagen targets Daiichi in cancer drug suit
22-10-2020
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14-11-2019
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
02-04-2019
svetlichniy_igor / Shutterstock.com
American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Daiichi Sankyo, American Regent, Pharmacosmos, patent infringement, Injectafer, Monoferric, anaemia,
